About the Company
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BCRX News
BCRX Apr 2024 1.000 call
Each of these hidden penny stock gems have the potential to provide triple digit growth to investors. Investors are forever on the lookout for Investments that can turn $1 into $2 or more. That is ...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., March 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today ...
Bluebird secures up to $175M in debt financing deal
In December, both bluebird and its competitor Boston-based Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) received FDA approval ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call Transcript February 26, 2024 BioCryst Pharmaceuticals, Inc ...
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 -- Partner Programs Continue to Report Positive Clinical ...
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Clearside Biomedical Q4 2023 Financial Results and Corporate Update Call. At this ...
13 Best Biotech Stocks To Buy Under $20
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list ...
Solid Biosciences (SLDB) Gets a Buy from Barclays
In a report released yesterday, Gena Wang from Barclays assigned a Buy rating to Solid Biosciences (SLDB – Research Report), with a price ...
Once-daily, oral berotralstat may rapidly and substantially reduce hereditary angioedema attacks: Study
USA: Once-daily, oral berotralstat (Orladeyo) treatment may lead to fast, considerable, and consistent hereditary angioedema ...
Regenxbio raised to Buy at RBC on pivot to Duchenne
Regenxbio (RGNX) stock rises as RBC Capital Markets upgrades the gene therapy developer, citing its potential against Duchenne muscular dystrophy. Read more here.
BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted ...
Loading the latest forecasts...